Mexico's controversial plan to dispense prescription drugs via vending machines sparks debate

Mexico’s Health Ministry has announced plans to install vending machines dispensing prescription medications in government-run health centres. The machines will provide 22 drugs for chronic illnesses like diabetes and high blood pressure. Officials claim the move aims to improve access, but critics argue it raises legal and health concerns. The initiative, outlined by Eduardo Clark, undersecretary for sectoral integration, will place the machines in health centres and other public facilities. Health Secretary David Kershenobich explained that the 22 selected medications target common conditions among older adults, including kidney disease and hypertension.

Public health policy specialist Adriana Rocha called the plan inadequate, warning that it fails to address the root cause of Mexico’s pharmaceutical crisis: persistent drug shortages in health centres. She also highlighted risks of improper medication use without professional oversight, which could worsen illnesses and undermine pharmacovigilance.

Health policy analyst Xavier Tello dismissed the proposal as 'absurd,' questioning how prescriptions would be verified through the machines. He also noted the lack of infrastructure for a health card system, which could complicate access. Additionally, Tello pointed out that digital illiteracy might exclude vulnerable groups, particularly women, from using the machines.

Legal concerns have also surfaced. Article 226 of Mexico’s General Health Law bans medication distribution from unregulated stalls or mobile units without proper controls. Meanwhile, Article 259 requires all facilities handling drugs to have a qualified professional ensuring product safety and oversight—something vending machines cannot provide. The vending machine scheme aims to streamline medication access for chronic conditions. However, critics argue it sidesteps deeper issues like drug shortages and legal compliance. Without clearer safeguards, the plan could face operational and regulatory hurdles.